Caillard V, Rouillon F, Viel J F, Markabi S
French University Antidepressant Study Group, Centre Esquirol, Caen, France.
Acta Psychiatr Scand. 1999 Jan;99(1):51-8. doi: 10.1111/j.1600-0447.1999.tb05384.x.
This study was designed to explore the dose-response relationship for clomipramine in patients with panic disorder, with or without agoraphobia. After 1 week of single-blind placebo pretreatment, 180 such patients were assigned to a multicentre placebo-controlled comparison of the effects of high and low doses of clomipramine, and were followed up for 8 weeks. In alleviating anxiety and panic disorder, both clomipramine doses were more efficacious than placebo for panic disorder and, to a lesser degree, for phobia. The lower dose was better tolerated and at least as effective as the higher dose, sometimes more so. These results indicate the clinically important possibility that low-dose clomipramine is effective and well tolerated.
本研究旨在探讨氯米帕明在伴有或不伴有广场恐惧症的惊恐障碍患者中的剂量-反应关系。在进行1周的单盲安慰剂预处理后,180名此类患者被分配到一个多中心、安慰剂对照的试验中,比较高剂量和低剂量氯米帕明的效果,并随访8周。在缓解焦虑和惊恐障碍方面,两种氯米帕明剂量对惊恐障碍均比安慰剂更有效,对恐惧症的效果稍差。低剂量的耐受性更好,且至少与高剂量一样有效,有时甚至更有效。这些结果表明,低剂量氯米帕明有效且耐受性良好,这在临床上具有重要意义。